Allopurinol dosage selection: relationships between dose and plasma oxipurinol and urate concentrations and urinary urate excretion
- PMID: 3190992
- PMCID: PMC1386564
- DOI: 10.1111/j.1365-2125.1988.tb03401.x
Allopurinol dosage selection: relationships between dose and plasma oxipurinol and urate concentrations and urinary urate excretion
Abstract
1. Allopurinol usage in 50 patients of a city teaching hospital was surveyed. 2. The plasma concentrations of oxipurinol and uric acid and the urinary production of uric acid were examined. 3. The daily doses of allopurinol ranged from 50 to 1200 mg but 83% of patients were taking 300 mg daily. 4. A wide range of plasma oxipurinol concentrations was observed from 2.8 to 55.8 mg l-1 with a mean +/- s.d. of 15.2 +/- 11.7 mg l-1. 5. The population studied included a high proportion of patients with renal impairment and creatinine clearance was a significant determinant of oxipurinol concentrations (P less than 0.005). 6. There was no significant correlation between plasma urate and plasma oxipurinol concentrations and only a few plasma urates were above the upper limit of the reference range of the laboratory. 7. It was apparent that many patients were taking unnecessarily high daily doses of allopurinol and that renal status was not always considered when deciding dosage regimens of allopurinol.
Similar articles
-
Clinical pharmacokinetics and pharmacodynamics of allopurinol and oxypurinol.Clin Pharmacokinet. 2007;46(8):623-44. doi: 10.2165/00003088-200746080-00001. Clin Pharmacokinet. 2007. PMID: 17655371 Review.
-
Plasma oxipurinol concentrations during allopurinol therapy.Br J Rheumatol. 1987 Dec;26(6):445-9. doi: 10.1093/rheumatology/26.6.445. Br J Rheumatol. 1987. PMID: 3690140
-
Dosage prescribing and plasma oxipurinol levels in patients receiving allopurinol therapy.Eur J Clin Pharmacol. 1990;39(4):419-21. doi: 10.1007/BF00315424. Eur J Clin Pharmacol. 1990. PMID: 2076730
-
Relationship between plasma oxipurinol concentrations and xanthine oxidase activity in volunteers dosed with allopurinol.Br J Clin Pharmacol. 1988 Oct;26(4):429-34. doi: 10.1111/j.1365-2125.1988.tb03402.x. Br J Clin Pharmacol. 1988. PMID: 3190993 Free PMC article. Clinical Trial.
-
Optimizing therapy with allopurinol: factors limiting hypouricemic efficacy.Am J Med Sci. 2008 Mar;335(3):219-26. doi: 10.1097/MAJ.0b013e31815acb10. Am J Med Sci. 2008. PMID: 18344696 Review.
Cited by
-
Pharmacokinetic and pharmacodynamic interaction between allopurinol and probenecid in healthy subjects.Clin Pharmacokinet. 2008;47(2):111-8. doi: 10.2165/00003088-200847020-00004. Clin Pharmacokinet. 2008. PMID: 18193917 Clinical Trial.
-
Pathophysiology, clinical presentation and treatment of gout.Drugs. 2006;66(12):1547-63. doi: 10.2165/00003495-200666120-00002. Drugs. 2006. PMID: 16956303 Review.
-
Xanthine oxidase and aldehyde oxidase contribute to allopurinol metabolism in rats.J Pharm Health Care Sci. 2022 Dec 8;8(1):31. doi: 10.1186/s40780-022-00262-x. J Pharm Health Care Sci. 2022. PMID: 36476607 Free PMC article.
-
1-Methylxanthine derived from theophylline as an in vivo biochemical probe of allopurinol effect.Br J Clin Pharmacol. 1991 Aug;32(2):238-41. doi: 10.1111/j.1365-2125.1991.tb03888.x. Br J Clin Pharmacol. 1991. PMID: 1931474 Free PMC article.
-
Clinical pharmacokinetics and pharmacodynamics of allopurinol and oxypurinol.Clin Pharmacokinet. 2007;46(8):623-44. doi: 10.2165/00003088-200746080-00001. Clin Pharmacokinet. 2007. PMID: 17655371 Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources